Seer to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
Seer, Inc. (Nasdaq: SEER) will participate in the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer, Inc. (Nasdaq: SEER) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. The management team is scheduled to present at 8:15 a.m. Pacific Time and will hold a Q&A session. A live webcast will be available on Seer's investor website, with an archived replay accessible afterward.
Seer specializes in developing products for proteomic analysis, including the Proteograph™ Product Suite, designed for deep and unbiased analysis in a streamlined manner. This product is intended for research use only.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -0.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will participate in the upcoming 40th Annual J.P. Morgan Healthcare Conference.
Seer’s management is scheduled to present and participate in a Q&A session on Monday, January 10 at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. A live webcast of the virtual session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.